Technical Analysis for CRL - Charles River Laboratories International, Inc.

Grade Last Price % Change Price Change
D 226.78 -0.34% -0.77
CRL closed down 0.34 percent on Friday, April 19, 2024, on 75 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 9
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal -0.34%
Lower Bollinger Band Walk Weakness -0.34%
Down 3 Days in a Row Weakness -0.34%
Down 4 Days in a Row Weakness -0.34%
Down 5 Days in a Row Weakness -0.34%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 20 hours ago
Up 1% about 24 hours ago
Gap Down Partially Closed 1 day ago
Gap Down Closed 1 day ago
Reversed from Down 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Charles River Laboratories International, Inc. Description

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment is involved in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, research animal diagnostic services, endotoxin and microbial detection products and services, and avian vaccine products and services. The PCS segment provides preclinical services, including both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: S&P 500 Biotechnology Life Sciences Pharmaceutical Drug Discovery In Vitro Lab Testing Metabolism Toxicology Laboratory Services Diagnostic Services Pathology Clinical Services Contract Research Organizations Pharmacokinetics Toxicology Testing Detection Products Drug Metabolism Pathology Services Pre Clinical Development Vaccine Products

Is CRL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 275.0
52 Week Low 161.65
Average Volume 547,758
200-Day Moving Average 215.84
50-Day Moving Average 252.23
20-Day Moving Average 251.88
10-Day Moving Average 240.00
Average True Range 6.82
RSI (14) 26.47
ADX 33.46
+DI 10.97
-DI 37.83
Chandelier Exit (Long, 3 ATRs) 254.31
Chandelier Exit (Short, 3 ATRs) 243.94
Upper Bollinger Bands 281.68
Lower Bollinger Band 222.08
Percent B (%b) 0.08
BandWidth 23.66
MACD Line -7.46
MACD Signal Line -3.58
MACD Histogram -3.8856
Fundamentals Value
Market Cap 11.63 Billion
Num Shares 51.3 Million
EPS 9.22
Price-to-Earnings (P/E) Ratio 24.60
Price-to-Sales 2.70
Price-to-Book 3.45
PEG Ratio 1.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 233.82
Resistance 3 (R3) 234.22 232.28 232.65
Resistance 2 (R2) 232.28 230.49 232.08 232.26
Resistance 1 (R1) 229.53 229.38 228.56 229.13 231.86
Pivot Point 227.59 227.59 227.10 227.39 227.59
Support 1 (S1) 224.84 225.80 223.87 224.43 221.70
Support 2 (S2) 222.90 224.69 222.69 221.30
Support 3 (S3) 220.14 222.90 220.91
Support 4 (S4) 219.74